Keywords: Novo Nordisk, Degludec, Glycemic control, Ph IIIa, Sanofi, Lantus
Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus
Article | 07 November 2011
Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from a 26-week Phase IIIa treat-to-target study comparing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
